KIM
MBRX icon

Kestra Investment Management’s Moleculin Biotech MBRX Stock Holding History

Kestra Investment Management’s Portfolio MBRX Stock Details MBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-1
Closed -$43 – 1229
2024
Q4 		$43 Buy
+1
New +$61 ﹤0.01% 1149

Other funds holding MBRX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Cetera Investment Advisers
Cetera Investment Advisers Schaumburg, Illinois $94B AUM 20.14% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Cambridge Investment Research Advisors
Cambridge Investment Research Advisors Fairfield, Iowa $44.6B AUM 28.94% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Truist Financial
Truist Financial Charlotte, North Carolina $83.7B AUM 27.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Kestra Investment Management's MBRX Position: Q1 2025 in Review

Kestra Investment Management sold out of Moleculin Biotech (MBRX) in Q1 2025, closing a stake of 1 share — an estimated $43 sold.

Kestra Investment Management first reported a position in MBRX in Q4 2024 and held it in 1 quarter. The position peaked at $43 in Q4 2024. 22 funds tracked by Wall St. Rank hold MBRX as of Q1 2025.

  • Kestra Investment Management reported no remaining Moleculin Biotech position as of Q1 2025 after selling out during the quarter.
  • Kestra Investment Management sold 1 Moleculin Biotech share in Q1 2025, an estimated $43.
  • Kestra Investment Management first reported a position in Moleculin Biotech in Q4 2024 and held it in 1 quarter.
  • Kestra Investment Management's Moleculin Biotech position peaked at $43 in Q4 2024.
  • 22 funds tracked by Wall St. Rank held Moleculin Biotech as of Q1 2025.

Based on Kestra Investment Management's 13F filing for Q1 2025, filed 16 May 2025.